Search
CX-052075
go.drugbank.com/drugs/DB31655Approved[L53408,L53423] The original approval was formulated with the JN.1 strain ([mRNA-1283]), but was ultimately updated to the sublineage LP.8.1.[L54586] … [L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from
Copper oxodotreotide Cu-64
go.drugbank.com/drugs/DB15873ApprovedCopper Cu 64 dotatate is a newly approved Cu labeled somatostatin analog and has several advantages over <sup>68</sup>Ga-labeled somatostatin analogs for positron emission tomography (PET). … [A220348] Further studies should be performed to compare the two tracers.
Primidone
go.drugbank.com/drugs/DB00794ApprovedVet approvedPrimidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. … [L11112] Primidone was developed by J Yule Bogue and H C Carrington in 1949.[A189522] Primidone was granted FDA Approval on 8 March 1954.[L11112]
Datopotamab deruxtecan
go.drugbank.com/drugs/DB16410ApprovedInvestigational[L52215] Datopotamab deruxtecan-dlnk (Datroway) was approved by the US FDA in January 2025 for the treatment of hormone receptor positive, HER2 negative unresectable or metastatic breast cancer. … [L52130,L52220] In June 2025, it was granted an accelerated approval by the FDA for the treatment non-small cell lung cancers with EGFR mutations.[L53623]
Pork collagen
go.drugbank.com/drugs/DB14100ApprovedThe surgical implantation shows a tolerable safety profile and efficacy up to 4 years, but it is not indicated for patients with osteoarthritis. … It serves as an alternative repair treatment for patients with inadequate response to pre-existing surgical methods.
Esterified estrogens
go.drugbank.com/drugs/DB09381ApprovedIt is being also for the prevention and treatment of osteoporosis. … Preparations contain 75% to 85% sodium estrone sulfate and 6% to 15% sodium equilin sulfate such that the total is not <90%.
Etravirine
go.drugbank.com/drugs/DB06414ApprovedInvestigationalOn March 26, 2012, approval was extended for use in treatment-experienced pediatric patients 6 to 18 years of age, weighing at least 16 kg. … On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 100mg tablets in the treatment of adult HIV-1 infection documented to be resistant to therapy with other NNRTIs and antiretroviral
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseCrizanlizumab
go.drugbank.com/drugs/DB15271ApprovedInvestigational[A187907] Crizanlizumab, or SEG101, is given once every 4 weeks and may improve patient adherence. It was developed by Novartis and was granted FDA approval on November 15, 2019. … [A187904] Though hydroxyurea has been shown to reduce the frequency of vaso-occlusive crises, adherence to this therapy is difficult due to adverse effects and the high variability of response to the drug
Guanethidine
go.drugbank.com/drugs/DB01170ApprovedWithdrawnIt is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues. … An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves.
Calaspargase pegol
go.drugbank.com/drugs/DB14730ApprovedInvestigationalCalaspargase pegol, by _Shire_ pharmaceuticals, was approved by the FDA on December 20, 2018 for acute lymphoblastic anemia (ALL) [L4890]. … Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) [A40270].
Categories: Compounds used in a research, industrial, or household setting